Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy

Area of Science:

• Molecular Biology
• Oncology
• Neuroscience
• Pharmacology

Background:

• Nicotinic acetylcholine receptors (nAChRs) are neurotransmitter receptors and ion channels first identified in 1970.
• nAChRs are implicated in smoking-induced cancers across various human cancer cell types.
• Specific nAChR subtypes, like α9-nAChR, play a role in breast cancer development.

Purpose of the Study:

• To investigate the role of nAChRs in cancer formation and progression.
• To explore the therapeutic potential of nAChR antagonists in cancer treatment and pain management.
• To evaluate natural compounds as inhibitors of nAChR signaling pathways in cancer.

Main Methods:

• In vitro and in vivo studies using cancer cell lines (lung, colon, bladder, breast).
• Administration of homopentameric nAChR inhibitors (e.g., methyllycaconitine, α-Bgtx).
• Utilized α9-nAChR-specific antagonists (e.g., Vc1.1) and natural compounds (e.g., garcinol, EGCG).

Main Results:

• Homopentameric nAChR inhibitors attenuated nicotine-induced proliferation, angiogenesis, and metastasis in various cancer cells.
• α9-nAChR antagonists demonstrated analgesic effects in animal models, with Vc1.1 entering Phase II clinical trials.
• Garcinol and EGCG inhibited nicotine- and estrogen-induced breast cancer cell proliferation by targeting the α9-nAChR pathway.

Conclusions:

• nAChRs are significant contributors to cancer development and progression.
• Specific nAChR antagonists show potential as dual-action agents for cancer therapy and pain relief.
• Further investigation into nAChRs and their antagonists is crucial for clinical translation in oncology.